Cargando…
P1138: COPANLISIB + RITUXIMAB VS RITUXIMAB + PLACEBO IN PATIENTS WITH RELAPSED INDOLENT NON-HODGKIN LYMPHOMA (NHL): UPDATED SAFETY AND EFFICACY FROM THE PHASE III CHRONOS-3 TRIAL
| Autores principales: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429570/ http://dx.doi.org/10.1097/01.HS9.0000847420.24995.43 |
| _version_ | 1784779496494202880 |
|---|---|
| author | Zinzani, P. L. Özcan, M. Sapunarova, K. Jurczak, W. Hamed, A. Bouabdallah, K. Saydam, G. Geissler, K. Szomor, Á. Lazaroiu, M. Salar, A. Tempescul, A. Nalcaci, M. Gercheva, L. Egyed, M. Panayiotidis, P. Mongay Soler, L. Cao, A. Phelps, C. H Childs, B. J Matasar, M. |
| author_facet | Zinzani, P. L. Özcan, M. Sapunarova, K. Jurczak, W. Hamed, A. Bouabdallah, K. Saydam, G. Geissler, K. Szomor, Á. Lazaroiu, M. Salar, A. Tempescul, A. Nalcaci, M. Gercheva, L. Egyed, M. Panayiotidis, P. Mongay Soler, L. Cao, A. Phelps, C. H Childs, B. J Matasar, M. |
| author_sort | Zinzani, P. L. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9429570 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94295702022-08-31 P1138: COPANLISIB + RITUXIMAB VS RITUXIMAB + PLACEBO IN PATIENTS WITH RELAPSED INDOLENT NON-HODGKIN LYMPHOMA (NHL): UPDATED SAFETY AND EFFICACY FROM THE PHASE III CHRONOS-3 TRIAL Zinzani, P. L. Özcan, M. Sapunarova, K. Jurczak, W. Hamed, A. Bouabdallah, K. Saydam, G. Geissler, K. Szomor, Á. Lazaroiu, M. Salar, A. Tempescul, A. Nalcaci, M. Gercheva, L. Egyed, M. Panayiotidis, P. Mongay Soler, L. Cao, A. Phelps, C. H Childs, B. J Matasar, M. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9429570/ http://dx.doi.org/10.1097/01.HS9.0000847420.24995.43 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Zinzani, P. L. Özcan, M. Sapunarova, K. Jurczak, W. Hamed, A. Bouabdallah, K. Saydam, G. Geissler, K. Szomor, Á. Lazaroiu, M. Salar, A. Tempescul, A. Nalcaci, M. Gercheva, L. Egyed, M. Panayiotidis, P. Mongay Soler, L. Cao, A. Phelps, C. H Childs, B. J Matasar, M. P1138: COPANLISIB + RITUXIMAB VS RITUXIMAB + PLACEBO IN PATIENTS WITH RELAPSED INDOLENT NON-HODGKIN LYMPHOMA (NHL): UPDATED SAFETY AND EFFICACY FROM THE PHASE III CHRONOS-3 TRIAL |
| title | P1138: COPANLISIB + RITUXIMAB VS RITUXIMAB + PLACEBO IN PATIENTS WITH RELAPSED INDOLENT NON-HODGKIN LYMPHOMA (NHL): UPDATED SAFETY AND EFFICACY FROM THE PHASE III CHRONOS-3 TRIAL |
| title_full | P1138: COPANLISIB + RITUXIMAB VS RITUXIMAB + PLACEBO IN PATIENTS WITH RELAPSED INDOLENT NON-HODGKIN LYMPHOMA (NHL): UPDATED SAFETY AND EFFICACY FROM THE PHASE III CHRONOS-3 TRIAL |
| title_fullStr | P1138: COPANLISIB + RITUXIMAB VS RITUXIMAB + PLACEBO IN PATIENTS WITH RELAPSED INDOLENT NON-HODGKIN LYMPHOMA (NHL): UPDATED SAFETY AND EFFICACY FROM THE PHASE III CHRONOS-3 TRIAL |
| title_full_unstemmed | P1138: COPANLISIB + RITUXIMAB VS RITUXIMAB + PLACEBO IN PATIENTS WITH RELAPSED INDOLENT NON-HODGKIN LYMPHOMA (NHL): UPDATED SAFETY AND EFFICACY FROM THE PHASE III CHRONOS-3 TRIAL |
| title_short | P1138: COPANLISIB + RITUXIMAB VS RITUXIMAB + PLACEBO IN PATIENTS WITH RELAPSED INDOLENT NON-HODGKIN LYMPHOMA (NHL): UPDATED SAFETY AND EFFICACY FROM THE PHASE III CHRONOS-3 TRIAL |
| title_sort | p1138: copanlisib + rituximab vs rituximab + placebo in patients with relapsed indolent non-hodgkin lymphoma (nhl): updated safety and efficacy from the phase iii chronos-3 trial |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429570/ http://dx.doi.org/10.1097/01.HS9.0000847420.24995.43 |
| work_keys_str_mv | AT zinzanipl p1138copanlisibrituximabvsrituximabplaceboinpatientswithrelapsedindolentnonhodgkinlymphomanhlupdatedsafetyandefficacyfromthephaseiiichronos3trial AT ozcanm p1138copanlisibrituximabvsrituximabplaceboinpatientswithrelapsedindolentnonhodgkinlymphomanhlupdatedsafetyandefficacyfromthephaseiiichronos3trial AT sapunarovak p1138copanlisibrituximabvsrituximabplaceboinpatientswithrelapsedindolentnonhodgkinlymphomanhlupdatedsafetyandefficacyfromthephaseiiichronos3trial AT jurczakw p1138copanlisibrituximabvsrituximabplaceboinpatientswithrelapsedindolentnonhodgkinlymphomanhlupdatedsafetyandefficacyfromthephaseiiichronos3trial AT hameda p1138copanlisibrituximabvsrituximabplaceboinpatientswithrelapsedindolentnonhodgkinlymphomanhlupdatedsafetyandefficacyfromthephaseiiichronos3trial AT bouabdallahk p1138copanlisibrituximabvsrituximabplaceboinpatientswithrelapsedindolentnonhodgkinlymphomanhlupdatedsafetyandefficacyfromthephaseiiichronos3trial AT saydamg p1138copanlisibrituximabvsrituximabplaceboinpatientswithrelapsedindolentnonhodgkinlymphomanhlupdatedsafetyandefficacyfromthephaseiiichronos3trial AT geisslerk p1138copanlisibrituximabvsrituximabplaceboinpatientswithrelapsedindolentnonhodgkinlymphomanhlupdatedsafetyandefficacyfromthephaseiiichronos3trial AT szomora p1138copanlisibrituximabvsrituximabplaceboinpatientswithrelapsedindolentnonhodgkinlymphomanhlupdatedsafetyandefficacyfromthephaseiiichronos3trial AT lazaroium p1138copanlisibrituximabvsrituximabplaceboinpatientswithrelapsedindolentnonhodgkinlymphomanhlupdatedsafetyandefficacyfromthephaseiiichronos3trial AT salara p1138copanlisibrituximabvsrituximabplaceboinpatientswithrelapsedindolentnonhodgkinlymphomanhlupdatedsafetyandefficacyfromthephaseiiichronos3trial AT tempescula p1138copanlisibrituximabvsrituximabplaceboinpatientswithrelapsedindolentnonhodgkinlymphomanhlupdatedsafetyandefficacyfromthephaseiiichronos3trial AT nalcacim p1138copanlisibrituximabvsrituximabplaceboinpatientswithrelapsedindolentnonhodgkinlymphomanhlupdatedsafetyandefficacyfromthephaseiiichronos3trial AT gercheval p1138copanlisibrituximabvsrituximabplaceboinpatientswithrelapsedindolentnonhodgkinlymphomanhlupdatedsafetyandefficacyfromthephaseiiichronos3trial AT egyedm p1138copanlisibrituximabvsrituximabplaceboinpatientswithrelapsedindolentnonhodgkinlymphomanhlupdatedsafetyandefficacyfromthephaseiiichronos3trial AT panayiotidisp p1138copanlisibrituximabvsrituximabplaceboinpatientswithrelapsedindolentnonhodgkinlymphomanhlupdatedsafetyandefficacyfromthephaseiiichronos3trial AT mongaysolerl p1138copanlisibrituximabvsrituximabplaceboinpatientswithrelapsedindolentnonhodgkinlymphomanhlupdatedsafetyandefficacyfromthephaseiiichronos3trial AT caoa p1138copanlisibrituximabvsrituximabplaceboinpatientswithrelapsedindolentnonhodgkinlymphomanhlupdatedsafetyandefficacyfromthephaseiiichronos3trial AT phelpsc p1138copanlisibrituximabvsrituximabplaceboinpatientswithrelapsedindolentnonhodgkinlymphomanhlupdatedsafetyandefficacyfromthephaseiiichronos3trial AT hchildsb p1138copanlisibrituximabvsrituximabplaceboinpatientswithrelapsedindolentnonhodgkinlymphomanhlupdatedsafetyandefficacyfromthephaseiiichronos3trial AT jmatasarm p1138copanlisibrituximabvsrituximabplaceboinpatientswithrelapsedindolentnonhodgkinlymphomanhlupdatedsafetyandefficacyfromthephaseiiichronos3trial |